Pulmonary Function Tests (PFTs) are essential diagnostic tools in the field of respiratory medicine, providing a wealth of information about lung function. However, their interpretation can be complex. This article aims to provide a comprehensive guide to interpreting PFTs for healthcare professionals.
Spirometry is the most common of the PFTs. It measures the volume and speed of air that can be inhaled and exhaled. Key parameters include Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1), and their ratio (FEV1/FVC). A reduced FEV1/FVC ratio indicates obstructive lung disease, while a reduced FVC with a normal FEV1/FVC ratio suggests restrictive lung disease.
These tests measure the lungs' ability to transfer gas from inhaled air to the red blood cells. The most common is the Diffusing Capacity for Carbon Monoxide (DLCO). Reduced DLCO may indicate conditions such as emphysema or pulmonary fibrosis.
These tests measure the total volume of air the lungs can hold (Total Lung Capacity, TLC), the volume remaining at the end of a normal exhalation (Functional Residual Capacity, FRC), and the volume of air remaining after a maximal exhalation (Residual Volume, RV). Increased RV and FRC with a normal TLC suggest air trapping, common in obstructive diseases.
These tests assess airway hyperresponsiveness, a hallmark of asthma. A significant decrease in FEV1 following exposure to a bronchoconstrictor indicates a positive test.
Interpreting PFTs is a skill that requires understanding of the tests' physiological basis and clinical implications. This guide provides a foundation for healthcare professionals to accurately interpret these tests, ultimately improving patient care in respiratory medicine. Continued education and practice are key to mastering this complex yet essential skill.
1.
Trial Supports Ivonescimab and Chemo for NSCLC Survival
2.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
3.
Lymph node transfer reduces arm swelling after breast cancer surgery, study shows
4.
Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.
5.
Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?
1.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
2.
Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Uncovering the Mysteries of the RDW Blood Test
5.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part II
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Navigating the Complexities of Ph Negative ALL - Part XIV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation